Platelet aggregation unchanged by lipoprotein-associated phospholipase A2 inhibition: Results from an in vitro study and two randomized phase I trials

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Shaddinger, Bonnie C ^a   Xu, Yanmei ^a   Roger, James H ^b   Macphee, Colin H ^a   Handel, Malcolm ^c   Baidoo, Charlotte A ^a   Magee, Mindy ^a   Lepore, John J ^a   Sprecher, Dennis L ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; PHOSPHOLIPASE A2; PLACEBO; RILAPLADIB;

ARTICLE; AUSTRALIA; CONCENTRATION RESPONSE; DRUG EXPOSURE; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; MEDIAN EFFECTIVE CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION;

ACETAMIDES; ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOPROTEINS; MALE; MODELS, BIOLOGICAL; NEW SOUTH WALES; PHOSPHOLIPASE A2 INHIBITORS; PLATELET AGGREGATION; QUINOLONES;

EID: 84899951261     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083094     Document Type: Article

References (32)

1. Wilensky RL, Macphee CH (2009) Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol 20: 415-420.
2. O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, et al. (2011) Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 162: 613-619 e611.
3. White H, Held C, Stewart R, Watson D, Harrington R, et al. (2010) Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 160: 655-661.
4. Vedin O, Hagstrom E, Stewart R, Brown R, Krug-Gourley S, et al. (2013) Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol 20: 678-685.
5. Blank ML, Lee T, Fitzgerald V, Snyder F (1981) A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem 256: 175-178. (Pubitemid 12207103)
6. Farr RS, Cox CP, Wardlow ML, Jorgensen R (1980) Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). Clin Immunol Immunopathol 15: 318-330. (Pubitemid 10174770)
7. Stafforini DM, Prescott SM, McIntyre TM (1987) Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem 262: 4223-4230. (Pubitemid 17102640)
8. Stafforini DM, McIntyre TM, Carter ME, Prescott SM (1987) Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262: 4215-4222. (Pubitemid 17102639)
9. Benveniste J, Le Couedic JP, Kamoun P (1975) Letter: Aggregation of human platelets by platelet-activating factor. Lancet 1: 344-345.
10. Chesney CM, Pifer DD, Byers LW, Muirhead EE (1982) Effect of platelet-activating factor (PAF) on human platelets. Blood 59: 582-585. (Pubitemid 12187478)
11. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr (2000) Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med 162: 523-527. (Pubitemid 30647194)
12. Naoki K, Asano K, Satoh N, Fukunaga K, Oguma T, et al. (2004) PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency. Biochem Biophys Res Commun 317: 205-210. (Pubitemid 38401985)
13. Ito S, Noguchi E, Shibasaki M, Yamakawa-Kobayashi K, Watanabe H, et al. (2002) Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma. J Hum Genet 47: 99-101. (Pubitemid 34296663)
14. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, et al. (1988) Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82: 1983-1991. (Pubitemid 19054946)
15. Satoh N, Asano K, Naoki K, Fukunaga K, Iwata M, et al. (1999) Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma. Am J Respir Crit Care Med 159: 974-979. (Pubitemid 29137804)
16. Stafforini DM, Numao T, Tsodikov A, Vaitkus D, Fukuda T, et al. (1999) Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest 103: 989-997. (Pubitemid 29169606)
17. Tsukioka K, Matsuzaki M, Nakamata M, Kayahara H, Nakagawa T (1996) Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. J Investig Allergol Clin Immunol 6: 22-29. (Pubitemid 26093607)
18. Vadas P, Gold M, Perelman B, Liss GM, Lack G, et al. (2008) Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 358: 28-35.
19. ClinicalTrials.gov (2008) The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). NCT00799903.
20. ClinicalTrials.gov (2009) The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52). NCT01000727.
21. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, et al. (2005) Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111: 570-575. (Pubitemid 40216483)
22. Schulz KF, Altman DG, Moher D, Group C (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152: 726-732.
23. Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, et al. (1987) Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 316: 1514-1518. (Pubitemid 17076236)
24. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, et al. (1996) Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97: 2784-2791. (Pubitemid 26197091)
25. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, et al. (2000) The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 66: 1522-1530. (Pubitemid 30463071)
26. Triggiani M, De Marino V, Sofia M, Faraone S, Ambrosio G, et al. (1997) Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am J Respir Crit Care Med 156: 94-100. (Pubitemid 27293172)
27. Sawyer DB, Andersen OS (1989) Platelet-activating factor is a general membrane perturbant. Biochim Biophys Acta 987: 129-132. (Pubitemid 20009007)
28. Snyder F (1995) Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1254: 231-249.
29. Yoshida H, Satoh K, Koyama M, Hiramoto M, Takamatsu S (1996) Deficiency of plasma platelet-activating factor acetylhydrolase: roles of blood cells. Am J Hematol 53: 158-164. (Pubitemid 26377733)
30. Hwang SB (1990) Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. J Lipid Mediat 2: 123-158.
31. Liu J, Chen R, Marathe GK, Febbraio M, Zou W, et al. (2011) Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/PAF acetylhydrolase. Circ Res 108: 469-477.
32. Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, et al. (2008) The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51: 1632-1641. (Pubitemid 351635837)